Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Whole body vibration added to treatment as usual is effective in adolescents with depression: a partly randomized, three-armed clinical trial in inpatients.

Wunram HL, Hamacher S, Hellmich M, Volk M, Jänicke F, Reinhard F, Bloch W, Zimmer P, Graf C, Schönau E, Lehmkuhl G, Bender S, Fricke O.

Eur Child Adolesc Psychiatry. 2018 May;27(5):645-662. doi: 10.1007/s00787-017-1071-2. Epub 2017 Nov 8.

PMID:
29119301
2.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

PMID:
27634692
3.

Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer.

Lebok P, Huber J, Burandt EC, Lebeau A, Marx AH, Terracciano L, Heilenkötter U, Jänicke F, Müller V, Paluchowski P, Geist S, Wilke C, Simon R, Sauter G, Quaas A.

Mol Med Rep. 2016 Aug;14(2):1443-50. doi: 10.3892/mmr.2016.5430. Epub 2016 Jun 23.

4.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N; EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Jun;27(6):1035-40. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.

PMID:
27022068
5.

Partial PTEN deletion is linked to poor prognosis in breast cancer.

Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von d Assen A, Müller V, Burandt E.

BMC Cancer. 2015 Dec 16;15:963. doi: 10.1186/s12885-015-1770-3.

6.

8p deletion is strongly linked to poor prognosis in breast cancer.

Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E.

Cancer Biol Ther. 2015;16(7):1080-7. doi: 10.1080/15384047.2015.1046025. Epub 2015 May 11.

7.

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.

Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.

Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.

PMID:
25721604
8.

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V.

Onco Targets Ther. 2014 Nov 28;7:2205-13. doi: 10.2147/OTT.S65344. eCollection 2014.

9.

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.

Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, Jänicke F.

BMC Cancer. 2014 Nov 4;14:806. doi: 10.1186/1471-2407-14-806.

10.

Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.

Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P.

Oncol Rep. 2014 Dec;32(6):2628-34. doi: 10.3892/or.2014.3523. Epub 2014 Oct 1.

PMID:
25270339
11.

Cyclin D1 gene amplification is highly homogeneous in breast cancer.

Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Wilczak W.

Breast Cancer. 2016 Jan;23(1):111-119. doi: 10.1007/s12282-014-0538-y. Epub 2014 May 27.

PMID:
24862872
12.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899.

PMID:
24827128
13.

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück HJ, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D, Welt A.

Breast Care (Basel). 2013 Jun;8(3):221-9. doi: 10.1159/000351692.

14.

c-FOS suppresses ovarian cancer progression by changing adhesion.

Oliveira-Ferrer L, Rößler K, Haustein V, Schröder C, Wicklein D, Maltseva D, Khaustova N, Samatov T, Tonevitsky A, Mahner S, Jänicke F, Schumacher U, Milde-Langosch K.

Br J Cancer. 2014 Feb 4;110(3):753-63. doi: 10.1038/bjc.2013.774. Epub 2013 Dec 5.

15.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.

Burandt E, Schreiber M, Stein A, Minner S, Clauditz TS, Bokemeyer C, Jänicke F, Fisch M, Izbicki JR, Knecht R, Sauter G, Stahl PR.

Genes Chromosomes Cancer. 2014 Mar;53(3):228-39. doi: 10.1002/gcc.22130. Epub 2013 Dec 5.

PMID:
24311521
16.

The prognostic significance of Jun transcription factors in ovarian cancer.

Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Jänicke F, Milde-Langosch K.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1673-80. doi: 10.1007/s00432-013-1489-y. Epub 2013 Aug 13.

PMID:
23942796
17.

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.

Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.

Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.

18.

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.

Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C; Chemo-N 0 Study Group.

Eur J Cancer. 2013 May;49(8):1825-35. doi: 10.1016/j.ejca.2013.01.007. Epub 2013 Mar 13.

PMID:
23490655
19.

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.

Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schütze D, Rausch A, Jänicke F, Milde-Langosch K, Müller V.

J Cancer Res Clin Oncol. 2013 May;139(5):809-16. doi: 10.1007/s00432-013-1382-8. Epub 2013 Feb 8.

PMID:
23392859
20.

Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.

Schütze D, Milde-Langosch K, Witzel I, Rody A, Karn T, Schmidt M, Choschzick M, Jänicke F, Müller V.

J Cancer Res Clin Oncol. 2013 May;139(5):747-54. doi: 10.1007/s00432-013-1378-4. Epub 2013 Jan 29.

PMID:
23358720
21.

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.

Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A.

Breast Cancer Res Treat. 2013 Feb;137(3):745-53. doi: 10.1007/s10549-013-2406-4. Epub 2013 Jan 16.

PMID:
23322234
22.

Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells.

Dippel V, Milde-Langosch K, Wicklein D, Schumacher U, Altevogt P, Oliveira-Ferrer L, Jänicke F, Schröder C.

J Cancer Res Clin Oncol. 2013 Jan;139(1):107-21. doi: 10.1007/s00432-012-1306-z. Epub 2012 Sep 16.

PMID:
22983139
23.

Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.

Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Ihnen M, Jänicke F, Milde-Langosch K.

Oncology. 2012;82(6):305-12. doi: 10.1159/000337222. Epub 2012 May 3.

PMID:
22555284
24.

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.

Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Müller V, Mahner S, Jänicke F, Woelber L, Milde-Langosch K.

BMC Cancer. 2012 Apr 4;12:140. doi: 10.1186/1471-2407-12-140.

25.

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.

Minner S, Luebke AM, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W.

Histopathology. 2012 Sep;61(3):445-53. doi: 10.1111/j.1365-2559.2012.04240.x. Epub 2012 Mar 28.

PMID:
22463702
26.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

27.

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C.

Expert Rev Mol Diagn. 2011 Jul;11(6):617-34. doi: 10.1586/erm.11.47. Review.

PMID:
21745015
28.

Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.

Witzel I, Kantelhardt EJ, Milde-Langosch K, Ihnen M, Zeitz J, Harbeck N, Jänicke F, Müller V.

Onkologie. 2011;34(6):304-8. doi: 10.1159/000328679. Epub 2011 May 13.

PMID:
21625183
29.

Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.

Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U, Milde-Langosch K.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1193-201. doi: 10.1007/s00432-011-0984-2. Epub 2011 May 18.

PMID:
21590495
30.

Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin.

Ihnen M, Kilic E, Köhler N, Löning T, Witzel I, Hagel C, Höller S, Kersten JF, Müller V, Jänicke F, Milde-Langosch K.

J Clin Pathol. 2011 Feb;64(2):146-52. doi: 10.1136/jcp.2010.082602.

PMID:
21262777
31.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.

Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K.

Breast Cancer Res Treat. 2011 Sep;129(2):347-60. doi: 10.1007/s10549-010-1219-y. Epub 2010 Oct 23.

PMID:
20972617
32.

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Jänicke F, Briassoulis E, Pectasides D, Rody A, Fountzilas G, Müller V.

Br J Cancer. 2010 Sep 28;103(7):1048-56. doi: 10.1038/sj.bjc.6605840. Epub 2010 Aug 24.

33.

Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.

Ihnen M, Köhler N, Kersten JF, Milde-Langosch K, Beck K, Höller S, Müller V, Witzel I, Jänicke F, Kilic E.

Dis Markers. 2010;28(2):71-8. doi: 10.3233/DMA-2010-0685.

34.

Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.

Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1709-18. doi: 10.1007/s00432-010-0829-4. Epub 2010 Mar 4.

PMID:
20204407
35.

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.

Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ.

Breast Cancer Res Treat. 2010 Apr;120(2):481-9. doi: 10.1007/s10549-010-0744-z. Epub 2010 Feb 4.

PMID:
20130985
36.

Gene amplification in ductal carcinoma in situ of the breast.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A.

Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22.

PMID:
20033484
37.

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.

Dose-Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C, Schwaiger M, Jänicke F, Untch M, Avril N.

Br J Cancer. 2010 Jan 5;102(1):35-41. doi: 10.1038/sj.bjc.6605427. Epub 2009 Nov 17.

38.

Expression and prognostic value of L1-CAM in breast cancer.

Schröder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz RM, Altevogt P, Krenkel S, Jänicke F, Milde-Langosch K.

Oncol Rep. 2009 Nov;22(5):1109-17.

PMID:
19787228
39.

Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.

Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K.

Oncol Rep. 2009 Jul;22(1):177-83.

PMID:
19513521
40.

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE.

J Clin Oncol. 2009 Jun 20;27(18):2938-45. doi: 10.1200/JCO.2008.20.3133. Epub 2009 Apr 13.

PMID:
19364964
41.

Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.

Knippen S, Löning T, Müller V, Schröder C, Jänicke F, Milde-Langosch K.

Anticancer Res. 2009 Jan;29(1):183-9.

42.

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.

Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K.

Br J Cancer. 2008 Oct 21;99(8):1269-75. doi: 10.1038/sj.bjc.6604650.

43.

The similarities of aromatase inhibitors outweigh the differences.

Jänicke F.

Anticancer Drugs. 2008 Mar;19 Suppl 2:S7-9. doi: 10.1097/01.cad.0000277874.73498.56. Review.

PMID:
18337642
44.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.

Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S.

BMC Cancer. 2008 Feb 26;8:62. doi: 10.1186/1471-2407-8-62.

45.

Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.

Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F, Milde-Langosch K.

Breast Cancer Res Treat. 2008 Dec;112(3):419-27. doi: 10.1007/s10549-007-9879-y. Epub 2008 Jan 3.

PMID:
18172759
46.

Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer.

Harbeck N, Schmitt M, Vetter M, Krol J, Paepke D, Uhlig M, Paepke S, Jänicke F, Geurts-Moespot A, von Minckwitz G, Sweep F, Thomssen C.

Breast Care (Basel). 2008;3(s2):11-15. Epub 2008 Oct 16. No abstract available.

47.

Trastuzumab in pregnancy associated with poor fetal outcome.

Witzel ID, Müller V, Harps E, Janicke F, Dewit M.

Ann Oncol. 2008 Jan;19(1):191-2. Epub 2007 Dec 15. Review. No abstract available.

PMID:
18084047
48.

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R.

Nat Genet. 2007 May;39(5):655-60. Epub 2007 Apr 8.

PMID:
17417639
49.

Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.

Milde-Langosch K, Janke S, Wagner I, Schröder C, Streichert T, Bamberger AM, Jänicke F, Löning T.

Breast Cancer Res Treat. 2008 Feb;107(3):337-47. Epub 2007 Mar 28.

PMID:
17393299
50.

Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature.

Ihnen M, Mahner S, Jänicke F, Schwarz J.

Int J Gynecol Cancer. 2007 Sep-Oct;17(5):957-63. Epub 2007 Mar 13. Review.

PMID:
17359294

Supplemental Content

Loading ...
Support Center